Back to speakers



City: Paris

Institution: Hôpital Beaujon


Biography of Tarik ASSELAH

Tarik Asselah is a Full Professor of Medicine and Hepatology at Hôpital Beaujon, Clichy, France, and at the University Paris Diderot, France. Tarik Asselah is the Head of Viral Hepatitis at INSERM (UMR 1149, Centre de Recherche sur l’Inflammation). He also holds a PhD in virology.

His fields of research include chronic liver diseases, translational medicineand treatment of HBV and HCV infections with new direct-acting antivirals, for which he has been involved as a coordinator/principal investigator in several clinical trials. He coordinated major international clinical trials on HCV Genotype 4 infection.

He has published more than 250 articles in the field of chronic liver diseases in major journals (NEJM, Lancet, Gastroenterology, Hepatology, Journal of Hepatology, etc…). (H-index = 60). He has been selected as a rising star in Gastroenteology in 2009 by the United European Gastroenterology(UEG) in appreciation of his outstanding scientific work. He received awards for his genomic studies on HCV in 2005 from the French Association for the Liver Disease (AFEF), and in 2019 from the Czech Hepatology Society.

PHC's participations

Monday, March 27th 2023


Bulevirtide in real life -

Tuesday, July 16th 2024


Tuesday, March 09th 2021

New advances in liver disease care (chairman)

Monday, March 08th 2021


New drugs for HDV

Monday, January 13th 2020

GILEAD SYMPOSIUM - The challenges of eliminating Hepatitis C from the North to the South (chairman)

Monday, January 13th 2020

ABBVIE SYMPOSIUM - Cascading HCV care into the community:
(12:30 Attendee lunch box pickup, 12:45- 13:45 Abbvie symposium) (chairman)

Welcome and Introduction

Building an HCV care network: the role of the hepatologist (chairman)

Meeting Summary and Close

13th PHC – 2020

Monday, January 13th 2020

New drugs for HDV -

Tuesday, January 14th 2020

LUNCH WORKSHOPS - 2. Management of hepatitis delta in 2020*: Room 243 -

12th PHC – 2019

Tuesday, January 15th 2019

Targets and new drugs for HBV -

Monday, January 14th 2019

Welcome and introduction

3rd PHC – 2009

Monday, January 19th 2009

New drugs : Enzyme inhibitors -

4th PHC – 2011

Monday, January 17th 2011

Advantages of new generation DAAs ? -

Tuesday, January 18th 2011

State of the Art lecture (chairman)

5th PHC – 2012

Monday, January 30th 2012

Interactive luncheons - Room 7 (chairman)

Tuesday, January 31st 2012

State of the Art Lecture (chairman)

State of the Art Lecture (chairman)

Advantages of new generation DAAs -

6th PHC – 2013

Monday, January 14th 2013

State of the art lecture (chairman)

Interactive luncheons - Room 6 (chairman)

IFN-free regimens -

7th PHC – 2014

Monday, January 13th 2014

State of the art lecture and Award (chairman)

Genotype 4 -

Advantages of 2nd generation triple therapy -

Tuesday, January 14th 2014

Interactive luncheons - Room 6 (chairman)

11th PHC – 2018

Monday, January 15th 2018

HEPATITIS C - SESSION 1 (chairman)

Treatment of HCV: 100 % cure ? -

Luncheon workshops - -

10th PHC – 2017

Monday, January 30th 2017

Universal Hepatitis C treatment: strategies for simplification -


8th PHC – 2015

Monday, January 12th 2015

State of the art lecture (chairman) -

INF-free therapy in naïve patients -

Take home messages (chairman) -

Tuesday, January 13th 2015

State of the art lecture (chairman)

Lunch Workshops - Room 253 (chairman)

Take home message (chairman)

9th PHC – 2016

Monday, January 11th 2016

State of the art lecture (chairman) -

How to improve the therapeutic strategies? -

Tuesday, January 12th 2016

Lunch Workshops - Room 253 -